ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements with these filters
Laurus Labs delivered record Q1FY27 revenue of ₹2,026 Cr, a 29% YoY increase, driven by robust CDMO growth. EBITDA margins expanded 700 bps YoY to 31.8% on favorable mix.
Laurus Labs has been assigned an ESG score of 63 out of 100 for FY 2026 by NSE Sustainability Ratings and Analytics Limited.
Laurus Labs has allotted 62,635 equity shares to employees upon the exercise of vested stock options under its ESOP schemes.
Laurus Labs announced the NCLT has issued an order regarding its Composite Scheme of Arrangement. The court directed notices be served for the upcoming September hearing.
Laurus Labs delivered record quarterly revenue and EBITDA margins, driven by strong CDMO commercial supplies and recovery in the affordable medicine portfolio.
Laurus Labs reported Q1 FY27 revenue of ₹2,026 Crore and EBITDA of ₹644 Crore. The results show 29% year-on-year revenue growth.
Laurus Labs delivered a strong Q1 FY27 with ₹2,026 Cr revenue (up 29% YoY), driven by robust CDMO growth. EBITDA margins expanded to 31.8% due to favorable product mix and operational leverage.
Independent Director Dr. Rajesh Koshy Chandy retired from Laurus Labs on July 26, 2026. This follows the completion of his second term.
Laurus Labs Ltd reported revenue from operations of ₹2,026 Cr (+29.1% YoY) and net profit of ₹362.1 Cr (+123.9% YoY) for Q1 FY27.
Routine quarterly shareholding pattern filing by Laurus Labs Ltd for the quarter ending June 30, 2026. No significant corporate action or financial event occurred.
Laurus Labs scheduled a board meeting on July 24, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.